Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

rTMS as Add on Treatment for Substance Use Disorders

NCT: NCT06963476 · COMPLETED

NCT IDNCT06963476
StatusCOMPLETED
Start Date2025-05-12
Completion2025-11-24
SponsorYale University (OTHER)
First posted
Last updated

Brief Summary

This pilot study is designed to test feasibility and superiority of rTMS types and target locations for the optimal rTMS intervention for individuals seeking treatment for Alcohol Use Disorder (AUD) or Opioid Use Disorder (OUD). The critical questions this study seeks to answer are: which rTMS type applied to l-dlPFC in OUD participants will induce the greatest reduction of opioid use post-treatment? Is inhibitory rTMS applied to medial prefrontal cortex (mPFC) more effective than excitatory rTMS applied to l-dlPFC at reducing alcohol use post treatment in AUD participants?

Frequently Asked Questions

What is rTMS as Add on Treatment for Substance Use Disorders?

rTMS as Add on Treatment for Substance Use Disorders is a clinical trial registered under NCT06963476. Current status: COMPLETED.

What is the status of NCT06963476?

The current status of NCT06963476 (rTMS as Add on Treatment for Substance Use Disorders) is: COMPLETED.

When did rTMS as Add on Treatment for Substance Use Disorders start?

rTMS as Add on Treatment for Substance Use Disorders started on 2025-05-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑